GERMANY - LSP portfolio company Idea AG signs $202m licensing deal with Alpharma

Life Sciences Partners portfolio company IDEA AG has agreed to sign a $202m licensing deal with an affiliate of American pharmaceutical Alpharma . The agreement involves the licensing of exclusive United States rights to Diractin as a prescription topical NSAID (non-steroidal anti-inflammatory drug) in the US. The license also includes access to IDEA's Transfersome technology platform for local drug delivery to targeted peripheral areas of the body. The payment will be made in several steps, subject to the results of clinical trials and US product approval.